Mysoline (Primidone)

Primidone, the active ingredient in Mysoline, is a barbiturate presented as an oral tablet for oral use. It treats generalized tonic‑clonic seizures and partial seizures in patients requiring antiepileptic therapy.

GNH USA supplies Mysoline as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Primidone is an antiepileptic drug used to control seizure activity in various epilepsy syndromes.

- Generalized tonic‑clonic seizures: reduces the frequency and severity of convulsive episodes. - Partial seizures: helps control focal seizure activity and prevents progression. - Epilepsy management: provides long‑term seizure control as part of a comprehensive treatment plan.

Primidone may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Dizziness: sensation of light‑headedness or imbalance. - Nausea: upset stomach or urge to vomit. - Ataxia: impaired coordination and unsteady gait.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome. - Blood dyscrasias: including agranulocytosis or aplastic anemia. - Respiratory depression: marked slowing of breathing, especially with other CNS depressants.

Before initiating Primidone therapy, consider the following safety measures.

- Monitor blood counts: regular CBC testing to detect hematologic abnormalities. - Assess liver function: periodic liver enzyme tests are recommended. - Avoid abrupt discontinuation: taper the dose under medical supervision to prevent withdrawal seizures. - Use caution in renal impairment: dose adjustments may be required. - Pregnancy: discuss risks with a healthcare provider before use. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Primidone can interact with several medications, influencing its efficacy and safety.

Major Interactions (Avoid): - Phenobarbital: additive central nervous system depression. - Alcohol: increased sedation and respiratory depression. - Other barbiturates: heightened risk of overdose and toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin): may raise primidone plasma levels. - CYP3A4 inducers (e.g., carbamazepine): may reduce primidone effectiveness.